Dimitar Divchev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dimitar Divchev has a total of 185 co-authors. Here are the top co-authors by number of shared publications:
- Ulrich Luesebrink
Department of Cardiology, University Hospital Marburg, Baldingerstraße, 35043 Marburg, Germany
7 shared publications - Christian Waechter
Department of Cardiology, University Hospital Marburg Philipps University Marburg Marburg Germany
6 shared publications - Georgios Chatzis
Department of Cardiology, Angiology, and Intensive Care Medicine, Philipps-Universität Marburg, Baldingerstraße, 35043 Marburg, Germany
5 shared publications - Konstantinos Karatolios
Philipps University of Marburg, Cardiology, Angiology, Internal Medicine and Intensive Care Unit, Cardiac Arrest Marburg , Marburg , Germany
5 shared publications - Styliani Syntila
Department of Cardiology, Angiology, and Intensive Care Medicine, Philipps-Universität Marburg, Baldingerstraße, 35043 Marburg, Germany
5 shared publications Tim Rehders
5 shared publications
Latest Publications
- Open Access
- 22 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2167
Predicting the Need for Intensive Care Unit Treatment After Successful Transcatheter Edge-to-Edge Mitral Valve Repair
Background/Objectives: Transcatheter edge-to-edge mitral valve repair (M-TEER) has emerged as an efficacious treatment modality among patients at high perioperative risk. Given the steady increase in procedures and the limited capacity for intensive care, there is a need to identify patients at high risk for postinterventional intensive care. Methods: All patients who underwent M-TEER between 2014 and 2023 were investigated. The intensive care unit (ICU) stay ended when patients met all the following criteria: no further need for catecholamine support, no oxygen requirement > 6 L O2/min, no indication for renal replacement therapy, and no delirium or relevant bleeding. Uni- and multivariable logistic regression analyses were used to identify independent predictors of the need for ICU treatment. Results: In total, 33% of patients (62/183) had an indication for ICU treatment after M-TEER. Patients with an indication for ICU treatment had significantly lower survival rates three years after M-TEER (37.4% [23/62] vs. 61.6% [75/121], p < 0.001) than patients without an ICU indication. A EuroSCORE II of >10% (OR 2.6, 95% CI 1.3–5.4, p = 0.006), a MitraScore of >3 (OR 2.5, 95% CI 1.2–5.2, p = 0.02), and a hospital stay of >5 days before M-TEER (OR 3.2, 95% CI 1.6–6.4, p < 0.001) were independently associated with the need for ICU treatment. Conclusions: One-third of the patients were indicated for ICU treatment, which was associated with a high mortality rate. On the basis of these predictors of required ICU care, tailored treatment strategies can be developed to improve treatment outcomes.
- 22 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2167
Open AccessPredicting the Need for Intensive Care Unit Treatment After Successful Transcatheter Edge-to-Edge Mitral Valve Repair
Background/Objectives: Transcatheter edge-to-edge mitral valve repair (M-TEER) has emerged as an efficacious treatment modality among patients at high perioperative risk. Given the steady increase in procedures and the limited capacity for intensive care, there is a need to identify patients at high risk for postinterventional intensive care. Methods: All patients who underwent M-TEER between 2014 and 2023 were investigated. The intensive care unit (ICU) stay ended when patients met all the following criteria: no further need for catecholamine support, no oxygen requirement > 6 L O2/min, no indication for renal replacement therapy, and no delirium or relevant bleeding. Uni- and multivariable logistic regression analyses were used to identify independent predictors of the need for ICU treatment. Results: In total, 33% of patients (62/183) had an indication for ICU treatment after M-TEER. Patients with an indication for ICU treatment had significantly lower survival rates three years after M-TEER (37.4% [23/62] vs. 61.6% [75/121], p < 0.001) than patients without an ICU indication. A EuroSCORE II of >10% (OR 2.6, 95% CI 1.3–5.4, p = 0.006), a MitraScore of >3 (OR 2.5, 95% CI 1.2–5.2, p = 0.02), and a hospital stay of >5 days before M-TEER (OR 3.2, 95% CI 1.6–6.4, p < 0.001) were independently associated with the need for ICU treatment. Conclusions: One-third of the patients were indicated for ICU treatment, which was associated with a high mortality rate. On the basis of these predictors of required ICU care, tailored treatment strategies can be developed to improve treatment outcomes.
- Open Access
- 9 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 1840
A Cross-Sectoral Telemedicine Network (sekTOR-HF) for Patients with Heart Failure
Objectives: Heart failure is associated with frequent hospital admissions and high mortality. Digital medical technologies could help to improve information exchange between healthcare providers and patients to prevent recurrent cardiac decompensation. Methods: Eligible patients aged between 18 and 85 (mean age 65 ± 12; 35.4% female) with symptomatic heart failure were included in this cross-sectoral telemedicine network (sekTOR-HF) study (n = 79) with a 12-month intervention period. Depending on the severity of heart failure at the time of inclusion, patients in the intervention group were labeled either as inpatients (NYHA III–IV) or outpatients (NYHA I–II). All patients not included served as the control group. Nearest Neighbor Propensity Score Matching was performed to obtain a control group of the same size. Patients in the intervention group received an electronic patient record with all relevant health data in an eHealth portal and the option to use learning modules. A coordinating network office supported all patients in the intervention group. Monitoring included patient self-measurement of blood pressure, weight, heart rate, and oxygen saturation and a digital electrocardiogram. The primary endpoint was all-cause rehospitalization in both groups. Results: The cumulative incidence for all-cause rehospitalization was lower in the intervention group compared to the control group (sHR 1.86; 95% CI: 1.12–3.09). There was no difference in all-cause mortality (HR 1.5; 95% CI: 0.53–4.21). Conclusions: Intervention management in this cross-sectoral telemedicine network led to a lower cumulative incidence of all-cause rehospitalization even in the early phase of intervention.
- 9 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 1840
Open AccessA Cross-Sectoral Telemedicine Network (sekTOR-HF) for Patients with Heart Failure
Objectives: Heart failure is associated with frequent hospital admissions and high mortality. Digital medical technologies could help to improve information exchange between healthcare providers and patients to prevent recurrent cardiac decompensation. Methods: Eligible patients aged between 18 and 85 (mean age 65 ± 12; 35.4% female) with symptomatic heart failure were included in this cross-sectoral telemedicine network (sekTOR-HF) study (n = 79) with a 12-month intervention period. Depending on the severity of heart failure at the time of inclusion, patients in the intervention group were labeled either as inpatients (NYHA III–IV) or outpatients (NYHA I–II). All patients not included served as the control group. Nearest Neighbor Propensity Score Matching was performed to obtain a control group of the same size. Patients in the intervention group received an electronic patient record with all relevant health data in an eHealth portal and the option to use learning modules. A coordinating network office supported all patients in the intervention group. Monitoring included patient self-measurement of blood pressure, weight, heart rate, and oxygen saturation and a digital electrocardiogram. The primary endpoint was all-cause rehospitalization in both groups. Results: The cumulative incidence for all-cause rehospitalization was lower in the intervention group compared to the control group (sHR 1.86; 95% CI: 1.12–3.09). There was no difference in all-cause mortality (HR 1.5; 95% CI: 0.53–4.21). Conclusions: Intervention management in this cross-sectoral telemedicine network led to a lower cumulative incidence of all-cause rehospitalization even in the early phase of intervention.
- Open Access
- 9 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (Supplement)
Biventricular unloading with Impella on top of veno-arterial membrane oxygenation improves short- and long-term survival in refractory post-cardiac arrest cardiogenic shock
Background: Patients with refractory post-cardiac arrest (CA) cardiogenic shock (RCS) may present with LV-failure, biventricular failure or even combined cardiopulmonary failure. Mechanical circulatory support (MCS) with Impella or veno-arterial membrane oxygenation (vaECMO) have emerged as an alternative strategy in order to stabilize the heart function without the detrimental effects of catecholamines or to bridge these patients in definite therapies. However, the selection of the appropriate MCS device should be tailored according to the underlying pathophysiology and properties of the respective MCS device. Especially vaECMO patients may show signs of LV overloading, causing pulmonary edema, LV distension and thus compromising LV myocardial recovery. Nowadays there is no data concerning the role of biventricular unloading with an Impella on top of a vaECMO in the homogenous group of post-CA RCS. Purpose: To report our experience from the combined use of Impella (2.5 and CP) on top of a vaECMO in the homogenous group of patients with post-CA RCS. Methods: Single center study of consecutive patients with biventricular unloading with Impella after initial vaECMO support over a 6-year period suffering from post-CA RCS. Propensity scoring matching analysis was used to account for the differences in baseline data between the two groups. Results: A total of 91 patients underwent vaECMO support for RCS, whereas in another 32 patients initial vaECMO support was escalated with an Impella (75% CP) (BiVent group). Mean age was 60.88 ± 9.8 and 98 (80%) patients were male. Survival rates were similar in both groups (hospital survival: BiVent 40.6% and vaECMO 33%, p=0.52; 12-month survival BiVent 37.5% and vaECMO 31.9%, p=0.67). After adjustment for baseline difference with propensity scoring matching analysis, survival rates were significantly better in the BiVent group (hospital and 12-month survival: BiVent 50% and vaECMO 17%, p=0.03 (Figure 1). Vasopressor doses and lactate levels decreased significantly more firmly in the BiVent group within 72 h on biventricular support compared to vaECMO (p<0.05). Moreover, the patients in the BiVent group demonstrated a greater functional recovery of the LV at 96 hours after admission compared to vaECMO patients (Figure 2). Conclusions: Impella on top of vaECMO improves short- and long-term survival in patients with post-cardiac arrest refractory cardiogenic shock leading to a better restoration of the left ventricle and end organ function.
- 9 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (Supplement)
Open AccessBiventricular unloading with Impella on top of veno-arterial membrane oxygenation improves short- and long-term survival in refractory post-cardiac arrest cardiogenic shock
Background: Patients with refractory post-cardiac arrest (CA) cardiogenic shock (RCS) may present with LV-failure, biventricular failure or even combined cardiopulmonary failure. Mechanical circulatory support (MCS) with Impella or veno-arterial membrane oxygenation (vaECMO) have emerged as an alternative strategy in order to stabilize the heart function without the detrimental effects of catecholamines or to bridge these patients in definite therapies. However, the selection of the appropriate MCS device should be tailored according to the underlying pathophysiology and properties of the respective MCS device. Especially vaECMO patients may show signs of LV overloading, causing pulmonary edema, LV distension and thus compromising LV myocardial recovery. Nowadays there is no data concerning the role of biventricular unloading with an Impella on top of a vaECMO in the homogenous group of post-CA RCS. Purpose: To report our experience from the combined use of Impella (2.5 and CP) on top of a vaECMO in the homogenous group of patients with post-CA RCS. Methods: Single center study of consecutive patients with biventricular unloading with Impella after initial vaECMO support over a 6-year period suffering from post-CA RCS. Propensity scoring matching analysis was used to account for the differences in baseline data between the two groups. Results: A total of 91 patients underwent vaECMO support for RCS, whereas in another 32 patients initial vaECMO support was escalated with an Impella (75% CP) (BiVent group). Mean age was 60.88 ± 9.8 and 98 (80%) patients were male. Survival rates were similar in both groups (hospital survival: BiVent 40.6% and vaECMO 33%, p=0.52; 12-month survival BiVent 37.5% and vaECMO 31.9%, p=0.67). After adjustment for baseline difference with propensity scoring matching analysis, survival rates were significantly better in the BiVent group (hospital and 12-month survival: BiVent 50% and vaECMO 17%, p=0.03 (Figure 1). Vasopressor doses and lactate levels decreased significantly more firmly in the BiVent group within 72 h on biventricular support compared to vaECMO (p<0.05). Moreover, the patients in the BiVent group demonstrated a greater functional recovery of the LV at 96 hours after admission compared to vaECMO patients (Figure 2). Conclusions: Impella on top of vaECMO improves short- and long-term survival in patients with post-cardiac arrest refractory cardiogenic shock leading to a better restoration of the left ventricle and end organ function.
- Open Access
- 9 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (Supplement)
Comparison of mechanical circulatory support with venoarterial extracorporeal membrane oxygenation or Impella for patients with cardiogenic shock: a propensity-matched analysis
Background: Percutaneous mechanical circulatory support (pMCS) devices are increasingly used in patients with cardiogenic shock (CS) in order to augment cardiac output, stabilize hemodynamics and ensure adequate organ perfusion avoiding or minimizing the detrimental effects of catecholamines to the vasculature. Impella and venoarterial extracorporeal membrane oxygenation (vaECMO) are the main representatives of the available pMCS devices. However, evidence from randomized studies comparing these devices are lacking and optimal choice of the device type in the setting of CS remains unclear. Purpose: Our aim was to conduct a head-to-head comparison of Impella with vaECMO in the setting of all-cause cardiogenic shock. Methods: Retrospective single center analysis of patients with CS over a 5-year period. Patients were assisted with either Impella 2.5/CP or vaECMO. Patients supported ultimately with both devices were analyzed according to the first device implanted. Primary outcomes were hospital and 6-month survival. Secondary endpoints were complications. Survival outcomes were compared using propensity-matched analysis to account for differences in baseline characteristics between both groups. Patients with ongoing resuscitation without return of spontaneous circulation on admission were excluded. Results: A total of 423 patients were included (Impella, n=300 and VA-ECMO, n=123). The main cause of CS was an acute myocardial infarction (372 patients, 87.4% in the Impella group and 83% in the vaECMO group), while 44,7% of the patients were prior resuscitated (39% Impella, 58% vaECMO). Survival rates were similar in both groups (hospital survival: Impella 47.7% and vaECMO 37.3%, p=0.07; 6-month survival Impella 45.7% and vaECMO 35.8%, p=0.07). After adjustment for baseline differences with a propensity scoring matching analysis, survival rates remained comparable between the two device groups (hospital survival: Impella 50.6% and vaECMO 38.6%, p=0.16; 6-month survival Impella 45.8% and vaECMO 38.6%, p=0.43) (Figure 1). Device-associated complications, such as access site bleeding and leg ischemia occurred more frequently in patients with vaECMO (17% versus 7.3%, p=0.004; 17% versus 7.7%, p=0.008). In the subgroup analysis, Impella and VA-ECMO did not demonstrate any statistically significant differences in the survival rates, expect for the group of prior resuscitation, where Impella appeared to be superior than vaECMO (Figure 2). Conclusions: In the biggest so far single center analysis, treatment with Impella 2.5/CP or VA-ECMO was associated with similar hospital and 6-month survival rates. Device-related access site vascular complications occurred more frequently in the vaECMO group. A randomized trial is warranted to examine the effects of these devices on outcomes and to determine the optimal device choice in patients with CS.
- 9 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (Supplement)
Open AccessComparison of mechanical circulatory support with venoarterial extracorporeal membrane oxygenation or Impella for patients with cardiogenic shock: a propensity-matched analysis
Background: Percutaneous mechanical circulatory support (pMCS) devices are increasingly used in patients with cardiogenic shock (CS) in order to augment cardiac output, stabilize hemodynamics and ensure adequate organ perfusion avoiding or minimizing the detrimental effects of catecholamines to the vasculature. Impella and venoarterial extracorporeal membrane oxygenation (vaECMO) are the main representatives of the available pMCS devices. However, evidence from randomized studies comparing these devices are lacking and optimal choice of the device type in the setting of CS remains unclear. Purpose: Our aim was to conduct a head-to-head comparison of Impella with vaECMO in the setting of all-cause cardiogenic shock. Methods: Retrospective single center analysis of patients with CS over a 5-year period. Patients were assisted with either Impella 2.5/CP or vaECMO. Patients supported ultimately with both devices were analyzed according to the first device implanted. Primary outcomes were hospital and 6-month survival. Secondary endpoints were complications. Survival outcomes were compared using propensity-matched analysis to account for differences in baseline characteristics between both groups. Patients with ongoing resuscitation without return of spontaneous circulation on admission were excluded. Results: A total of 423 patients were included (Impella, n=300 and VA-ECMO, n=123). The main cause of CS was an acute myocardial infarction (372 patients, 87.4% in the Impella group and 83% in the vaECMO group), while 44,7% of the patients were prior resuscitated (39% Impella, 58% vaECMO). Survival rates were similar in both groups (hospital survival: Impella 47.7% and vaECMO 37.3%, p=0.07; 6-month survival Impella 45.7% and vaECMO 35.8%, p=0.07). After adjustment for baseline differences with a propensity scoring matching analysis, survival rates remained comparable between the two device groups (hospital survival: Impella 50.6% and vaECMO 38.6%, p=0.16; 6-month survival Impella 45.8% and vaECMO 38.6%, p=0.43) (Figure 1). Device-associated complications, such as access site bleeding and leg ischemia occurred more frequently in patients with vaECMO (17% versus 7.3%, p=0.004; 17% versus 7.7%, p=0.008). In the subgroup analysis, Impella and VA-ECMO did not demonstrate any statistically significant differences in the survival rates, expect for the group of prior resuscitation, where Impella appeared to be superior than vaECMO (Figure 2). Conclusions: In the biggest so far single center analysis, treatment with Impella 2.5/CP or VA-ECMO was associated with similar hospital and 6-month survival rates. Device-related access site vascular complications occurred more frequently in the vaECMO group. A randomized trial is warranted to examine the effects of these devices on outcomes and to determine the optimal device choice in patients with CS.
- Open Access
- 25 October 2022
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 9 (11) , 366
Antithrombotic Treatment and Its Association with Outcome in a Multicenter Cohort of Transcatheter Edge-to-Edge Mitral Valve Repair Patients
Transcatheter edge-to-edge mitral valve repair (TEER) has become established as a safe and efficacious therapy for severe mitral regurgitation (MR) in high-risk patients. Despite its widespread use, postprocedural antithrombotic therapy (ATT) still to date is based on local expertise rather than evidence. In a multicenter, observational cohort study, 646 consecutive patients undergoing TEER were enrolled; 609 patients were successfully treated and antithrombotic therapy analyzed; 449 patients (73.7%) were previously treated with oral anticoagulants (OAC) due to the high prevalence of atrial fibrillation (459/609, 75.4%). Postprocedural ATT in patients previously treated with OAC consisted of no additional, additional single (SAPT) or dual antiplatelet therapy (DAPT) in 146/449 (33.6%), 248/449 (55.2%) and 55/449 (12.2%), respectively. There were 234/449 (52.1%) patients treated with vitamin-k antagonists (VKA) and 215/449 (47.9%) with nonvitamin-k antagonist oral anticoagulants (NOAC). One hundred sixty patients (26.3%) had no prior indication for OAC and were predominantly treated with DAPT (132/160, 82.5%). Use of SAPT (17/160, 10.6%) and no APT (11/160, 6.9%) was marginal. No statistically significant differences in terms of in-hospital mortality or the rate of major adverse cardiac and cerebrovascular events (MACCE) between the different antithrombotic therapy regimens were observed. Multiple Cox regression analysis showed a statistically significant decreased risk for all-cause mortality after a median follow-up of 419 days for OAC monotherapy (HR 0.6, 95%-CI 0.5–0.9, p = 0.04). This study provides evidence for a more favorable long-term outcome of OAC monotherapy in patients with an indication for OAC and reiterates the urgent need for randomized controlled trials on the optimal antithrombotic treatment of TEER patients.
- 25 October 2022
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 9 (11) , 366
Open AccessAntithrombotic Treatment and Its Association with Outcome in a Multicenter Cohort of Transcatheter Edge-to-Edge Mitral Valve Repair Patients
Transcatheter edge-to-edge mitral valve repair (TEER) has become established as a safe and efficacious therapy for severe mitral regurgitation (MR) in high-risk patients. Despite its widespread use, postprocedural antithrombotic therapy (ATT) still to date is based on local expertise rather than evidence. In a multicenter, observational cohort study, 646 consecutive patients undergoing TEER were enrolled; 609 patients were successfully treated and antithrombotic therapy analyzed; 449 patients (73.7%) were previously treated with oral anticoagulants (OAC) due to the high prevalence of atrial fibrillation (459/609, 75.4%). Postprocedural ATT in patients previously treated with OAC consisted of no additional, additional single (SAPT) or dual antiplatelet therapy (DAPT) in 146/449 (33.6%), 248/449 (55.2%) and 55/449 (12.2%), respectively. There were 234/449 (52.1%) patients treated with vitamin-k antagonists (VKA) and 215/449 (47.9%) with nonvitamin-k antagonist oral anticoagulants (NOAC). One hundred sixty patients (26.3%) had no prior indication for OAC and were predominantly treated with DAPT (132/160, 82.5%). Use of SAPT (17/160, 10.6%) and no APT (11/160, 6.9%) was marginal. No statistically significant differences in terms of in-hospital mortality or the rate of major adverse cardiac and cerebrovascular events (MACCE) between the different antithrombotic therapy regimens were observed. Multiple Cox regression analysis showed a statistically significant decreased risk for all-cause mortality after a median follow-up of 419 days for OAC monotherapy (HR 0.6, 95%-CI 0.5–0.9, p = 0.04). This study provides evidence for a more favorable long-term outcome of OAC monotherapy in patients with an indication for OAC and reiterates the urgent need for randomized controlled trials on the optimal antithrombotic treatment of TEER patients.
- 30 May 2022
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 147 (11) , 704-710
Was ist neu bei Perikard-Erkrankungen?
Ätiologie und klinische Präsentation Zuletzt in den Fokus gerückt ist die perikardiale Beteiligung im Rahmen einer SARS-CoV-2-Infektion. Zudem werden Perikarditiden nach stattgehabter Corona-Impfung berichtet. Diagnostik Zur Diagnosestellung stehen unverändert das EKG sowie die Bildgebung mittels Echokardiografie, Kardio-CT und -MRT im Vordergrund. Therapie Als First-Line-Therapie sind weiterhin NSAR und Colchicin vorgesehen; bei Unverträglichkeiten können ebenfalls Glukokortikoide (Second Line) gegeben werden. Im Falle von Rezidiven, welche nicht auf diese Therapien ansprechen, kommen intravenöse Immunglobuline, Anakinra oder Azathioprin (Third Line) zum Einsatz. Die Ultima Ratio stellt die Perikard-Ektomie dar. Die Entwicklung und das Einsetzen von Medikamenten, die sich spezifisch gegen einzelne Komponenten molekularer Signalwege richten, werden in Zukunft immer mehr an Bedeutung erlangen. Pericardial disease represents a large diversity of inflammation related injury of the pericardium. Multifactorial causes may contribute to acute and recurrent pericarditis, pericardial effusion without major hemodynamic compromise, cardiac tamponade or constrictive pericarditis. Currently, inflammatory pericardial pathologies are observed in cases of SARS-CoV-2-infection or after vaccination. Beside established anti-inflammatory therapeutic strategies with NSAID, corticosteroids and colchicine, auto-inflammation and inflammasomes seam to offer more specific targets for advanced treatment options. Article published online: 30 May 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 30 May 2022
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 147 (11) , 704-710
Was ist neu bei Perikard-Erkrankungen?
Ätiologie und klinische Präsentation Zuletzt in den Fokus gerückt ist die perikardiale Beteiligung im Rahmen einer SARS-CoV-2-Infektion. Zudem werden Perikarditiden nach stattgehabter Corona-Impfung berichtet. Diagnostik Zur Diagnosestellung stehen unverändert das EKG sowie die Bildgebung mittels Echokardiografie, Kardio-CT und -MRT im Vordergrund. Therapie Als First-Line-Therapie sind weiterhin NSAR und Colchicin vorgesehen; bei Unverträglichkeiten können ebenfalls Glukokortikoide (Second Line) gegeben werden. Im Falle von Rezidiven, welche nicht auf diese Therapien ansprechen, kommen intravenöse Immunglobuline, Anakinra oder Azathioprin (Third Line) zum Einsatz. Die Ultima Ratio stellt die Perikard-Ektomie dar. Die Entwicklung und das Einsetzen von Medikamenten, die sich spezifisch gegen einzelne Komponenten molekularer Signalwege richten, werden in Zukunft immer mehr an Bedeutung erlangen. Pericardial disease represents a large diversity of inflammation related injury of the pericardium. Multifactorial causes may contribute to acute and recurrent pericarditis, pericardial effusion without major hemodynamic compromise, cardiac tamponade or constrictive pericarditis. Currently, inflammatory pericardial pathologies are observed in cases of SARS-CoV-2-infection or after vaccination. Beside established anti-inflammatory therapeutic strategies with NSAID, corticosteroids and colchicine, auto-inflammation and inflammasomes seam to offer more specific targets for advanced treatment options. Article published online: 30 May 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 28 October 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (21) , 5044
Impact of Rhythm vs. Rate Control in Atrial Fibrillation on the Long-Term Outcome of Patients Undergoing Transcatheter Edge-to-Edge Mitral Valve Repair
Atrial fibrillation (AF) is a highly prevalent comorbidity in patients with severe mitral valve regurgitation (MR) undergoing transcatheter mitral valve repair (TMVR) and has been shown to significantly worsen their outcome. However, data on the impact of AF treatment strategy in this rapidly growing cohort of patients is unknown. In a multicenter, observational cohort study, 542 consecutive patients undergoing TMVR were enrolled, and subsequently, comprehensive survival analyses according to AF status and therapy were performed using propensity score matching and Cox regression. In the analyzed cohort, 373 (73.3%) of the TMVR patients had concomitant AF. Of these patients, 212 (59%) were on rate control therapy and 161 (41%) were on rhythm control therapy. At 3 years, significantly reduced cumulative survival was observed for patients on rhythm compared to patients on rate control (46.7% (75/161) vs. 56.5% (91/161), p = 0.032). Amiodarone was used to a substantial extent for rhythm control and found to be an independent mortality predictor (Hazard Ratio 1.5, 95%CI 1.1–2.1, p = 0.04). The adverse outcome of concomitant AF in TMVR patients was confirmed (AF: 47.3% (126/266) vs. non-AF: 58.3% (78/133), p = 0.047). Rhythm control achieved almost exclusively pharmacologically is associated with an adverse outcome compared to the rate control of AF in TMVR. This raises awareness of the importance of AF and its treatment, as this seems to be a promising key point for improving the prognosis of TMVR patients.
- 28 October 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (21) , 5044
Open AccessImpact of Rhythm vs. Rate Control in Atrial Fibrillation on the Long-Term Outcome of Patients Undergoing Transcatheter Edge-to-Edge Mitral Valve Repair
Atrial fibrillation (AF) is a highly prevalent comorbidity in patients with severe mitral valve regurgitation (MR) undergoing transcatheter mitral valve repair (TMVR) and has been shown to significantly worsen their outcome. However, data on the impact of AF treatment strategy in this rapidly growing cohort of patients is unknown. In a multicenter, observational cohort study, 542 consecutive patients undergoing TMVR were enrolled, and subsequently, comprehensive survival analyses according to AF status and therapy were performed using propensity score matching and Cox regression. In the analyzed cohort, 373 (73.3%) of the TMVR patients had concomitant AF. Of these patients, 212 (59%) were on rate control therapy and 161 (41%) were on rhythm control therapy. At 3 years, significantly reduced cumulative survival was observed for patients on rhythm compared to patients on rate control (46.7% (75/161) vs. 56.5% (91/161), p = 0.032). Amiodarone was used to a substantial extent for rhythm control and found to be an independent mortality predictor (Hazard Ratio 1.5, 95%CI 1.1–2.1, p = 0.04). The adverse outcome of concomitant AF in TMVR patients was confirmed (AF: 47.3% (126/266) vs. non-AF: 58.3% (78/133), p = 0.047). Rhythm control achieved almost exclusively pharmacologically is associated with an adverse outcome compared to the rate control of AF in TMVR. This raises awareness of the importance of AF and its treatment, as this seems to be a promising key point for improving the prognosis of TMVR patients.
- Open Access
- 18 March 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (6) , 1273
Left Ventricle Architecture and Valvular Integrity Following Microaxial Mechanical Support: A Two-Year Follow-Up Study
Although the use of microaxilar mechanical circulatory support systems may improve the outcome of patients with cardiogenic shock (CS), little is known about its effect on the long-term structural integrity of left ventricular (LV) valves as well as on the development of LV-architecture. Therefore, we aimed to study the integrity of the LV valves and architecture and function after Impella support. Thus, 84 consecutive patients were monitored over two years having received ImpellaTM CP (n = 24) or 2.5 (n = 60) for refractory CS (n = 62) or for high-risk percutaneous coronary interventions (n = 22) followed by optimal medical treatment. Beside a significant increase in LV ejection fraction after two years (p ≤ 0.03 vs. pre-implantation), we observed a statistically significant decrease in LV dilation (p < 0.001) and severity of mitral valve regurgitation (p = 0.007) in the two-year follow-up period, suggesting an improved LV architecture. Neither the duration of support, nor the size of the Impella device or the indication for its use revealed any devastating impact on aortic or mitral valve integrity. These findings indicate that Impella device is a safe means of support of LV-function without detrimental long-term effects on the structural integrity of LV valves regardless of the size of the device or the indication of support.
- 18 March 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (6) , 1273
Open AccessLeft Ventricle Architecture and Valvular Integrity Following Microaxial Mechanical Support: A Two-Year Follow-Up Study
Although the use of microaxilar mechanical circulatory support systems may improve the outcome of patients with cardiogenic shock (CS), little is known about its effect on the long-term structural integrity of left ventricular (LV) valves as well as on the development of LV-architecture. Therefore, we aimed to study the integrity of the LV valves and architecture and function after Impella support. Thus, 84 consecutive patients were monitored over two years having received ImpellaTM CP (n = 24) or 2.5 (n = 60) for refractory CS (n = 62) or for high-risk percutaneous coronary interventions (n = 22) followed by optimal medical treatment. Beside a significant increase in LV ejection fraction after two years (p ≤ 0.03 vs. pre-implantation), we observed a statistically significant decrease in LV dilation (p < 0.001) and severity of mitral valve regurgitation (p = 0.007) in the two-year follow-up period, suggesting an improved LV architecture. Neither the duration of support, nor the size of the Impella device or the indication for its use revealed any devastating impact on aortic or mitral valve integrity. These findings indicate that Impella device is a safe means of support of LV-function without detrimental long-term effects on the structural integrity of LV valves regardless of the size of the device or the indication of support.
- Open Access
- 13 February 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (4) , 747
Biventricular Unloading with Impella and Venoarterial Extracorporeal Membrane Oxygenation in Severe Refractory Cardiogenic Shock: Implications from the Combined Use of the Devices and Prognostic Risk Factors of Survival
Since mechanical circulatory support (MCS) devices have become integral component in the therapy of refractory cardiogenic shock (RCS), we identified 67 patients in biventricular support with Impella and venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) for RCS between February 2013 and December 2019 and evaluated the risk factors of mortality in this setting. Mean age was 61.07 ± 10.7 and 54 (80.6%) patients were male. Main cause of RCS was acute myocardial infarction (AMI) (74.6%), while 44 (65.7%) were resuscitated prior to admission. The mean Simplified Acute Physiology Score II (SAPS II) and Sequential Organ Failure Assessment Score (SOFA) score on admission was 73.54 ± 16.03 and 12.25 ± 2.71, respectively, corresponding to an expected mortality of higher than 80%. Vasopressor doses and lactate levels were significantly decreased within 72 h on biventricular support (p < 0.05 for both). Overall, 17 (25.4%) patients were discharged to cardiac rehabilitation and 5 patients (7.5%) were bridged successfully to ventricular assist device implantation, leading to a total of 32.8% survival on hospital discharge. The 6-month survival was 31.3%. Lactate > 6 mmol/L, vasoactive score > 100 and pH < 7.26 on initiation of biventricular support, as well as Charlson comorbity index > 3 and prior resuscitation were independent predictors of survival. In conclusion, biventricular support with Impella and VA-ECMO in patients with RCS is feasible and efficient leading to a better survival than predicted through traditional risk scores, mainly via significant hemodynamic improvement and reduction in lactate levels.
- 13 February 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (4) , 747
Open AccessBiventricular Unloading with Impella and Venoarterial Extracorporeal Membrane Oxygenation in Severe Refractory Cardiogenic Shock: Implications from the Combined Use of the Devices and Prognostic Risk Factors of Survival
Since mechanical circulatory support (MCS) devices have become integral component in the therapy of refractory cardiogenic shock (RCS), we identified 67 patients in biventricular support with Impella and venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) for RCS between February 2013 and December 2019 and evaluated the risk factors of mortality in this setting. Mean age was 61.07 ± 10.7 and 54 (80.6%) patients were male. Main cause of RCS was acute myocardial infarction (AMI) (74.6%), while 44 (65.7%) were resuscitated prior to admission. The mean Simplified Acute Physiology Score II (SAPS II) and Sequential Organ Failure Assessment Score (SOFA) score on admission was 73.54 ± 16.03 and 12.25 ± 2.71, respectively, corresponding to an expected mortality of higher than 80%. Vasopressor doses and lactate levels were significantly decreased within 72 h on biventricular support (p < 0.05 for both). Overall, 17 (25.4%) patients were discharged to cardiac rehabilitation and 5 patients (7.5%) were bridged successfully to ventricular assist device implantation, leading to a total of 32.8% survival on hospital discharge. The 6-month survival was 31.3%. Lactate > 6 mmol/L, vasoactive score > 100 and pH < 7.26 on initiation of biventricular support, as well as Charlson comorbity index > 3 and prior resuscitation were independent predictors of survival. In conclusion, biventricular support with Impella and VA-ECMO in patients with RCS is feasible and efficient leading to a better survival than predicted through traditional risk scores, mainly via significant hemodynamic improvement and reduction in lactate levels.
- Open Access
- 18 January 2021
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2021, 1-10
Comparison of Mortality Risk Models in Patients with Postcardiac Arrest Cardiogenic Shock and Percutaneous Mechanical Circulatory Support
Background. Although scoring systems are widely used to predict outcomes in postcardiac arrest cardiogenic shock (CS) after out-of-hospital cardiac arrest (OHCA) complicating acute myocardial infarction (AMI), data concerning the accuracy of these scores to predict mortality of patients treated with Impella in this setting are lacking. Thus, we aimed to evaluate as well as to compare the prognostic accuracy of acute physiology and chronic health II (APACHE II), simplified acute physiology score II (SAPS II), sepsis-related organ failure assessment (SOFA), the intra-aortic balloon pump (IABP), CardShock, the prediction of cardiogenic shock outcome for AMI patients salvaged by VA-ECMO (ENCOURAGE), and the survival after venoarterial extracorporeal membrane oxygenation (SAVE) score in patients with OHCA refractory CS due to an AMI treated with Impella 2.5 or CP. Methods. Retrospective study of 65 consecutive Impella 2.5 and 32 CP patients treated in our cardiac arrest center from September 2015 until June 2020. Results. Overall survival to discharge was 44.3. The expected mortality according to scores was SOFA 70, SAPS II 90, IABP shock 55, CardShock 80, APACHE II 85, ENCOURAGE 50, and SAVE score 70 in the 2.5 group; SOFA 70, SAPS II 85, IABP shock 55, CardShock 80, APACHE II 85, ENCOURAGE 75, and SAVE score 70 in the CP group. The ENCOURAGE score was the most effective predictive model of mortality outcome presenting a moderate area under the curve (AUC) of 0.79, followed by the CardShock, APACHE II, IABP, and SAPS score. These derived an AUC between 0.71 and 0.78. The SOFA and the SAVE scores failed to predict the outcome in this particular setting of refractory CS after OHCA due to an AMI. Conclusion. The available intensive care and newly developed CS scores offered only a moderate prognostic accuracy for outcomes in OHCA patients with refractory CS due to an AMI treated with Impella. A new score is needed in order to guide the therapy in these patients.
- 18 January 2021
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2021, 1-10
Open AccessComparison of Mortality Risk Models in Patients with Postcardiac Arrest Cardiogenic Shock and Percutaneous Mechanical Circulatory Support
Background. Although scoring systems are widely used to predict outcomes in postcardiac arrest cardiogenic shock (CS) after out-of-hospital cardiac arrest (OHCA) complicating acute myocardial infarction (AMI), data concerning the accuracy of these scores to predict mortality of patients treated with Impella in this setting are lacking. Thus, we aimed to evaluate as well as to compare the prognostic accuracy of acute physiology and chronic health II (APACHE II), simplified acute physiology score II (SAPS II), sepsis-related organ failure assessment (SOFA), the intra-aortic balloon pump (IABP), CardShock, the prediction of cardiogenic shock outcome for AMI patients salvaged by VA-ECMO (ENCOURAGE), and the survival after venoarterial extracorporeal membrane oxygenation (SAVE) score in patients with OHCA refractory CS due to an AMI treated with Impella 2.5 or CP. Methods. Retrospective study of 65 consecutive Impella 2.5 and 32 CP patients treated in our cardiac arrest center from September 2015 until June 2020. Results. Overall survival to discharge was 44.3. The expected mortality according to scores was SOFA 70, SAPS II 90, IABP shock 55, CardShock 80, APACHE II 85, ENCOURAGE 50, and SAVE score 70 in the 2.5 group; SOFA 70, SAPS II 85, IABP shock 55, CardShock 80, APACHE II 85, ENCOURAGE 75, and SAVE score 70 in the CP group. The ENCOURAGE score was the most effective predictive model of mortality outcome presenting a moderate area under the curve (AUC) of 0.79, followed by the CardShock, APACHE II, IABP, and SAPS score. These derived an AUC between 0.71 and 0.78. The SOFA and the SAVE scores failed to predict the outcome in this particular setting of refractory CS after OHCA due to an AMI. Conclusion. The available intensive care and newly developed CS scores offered only a moderate prognostic accuracy for outcomes in OHCA patients with refractory CS due to an AMI treated with Impella. A new score is needed in order to guide the therapy in these patients.